GRI Bio (GRI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
29 Dec, 2025Executive summary
Special Meeting scheduled for January 15, 2026, to be held virtually to maximize participation and efficiency.
Two key proposals: a reverse stock split authorization and potential adjournment if more votes are needed.
Board recommends voting in favor of both proposals to maintain Nasdaq listing and flexibility.
Voting matters and shareholder proposals
Proposal 1: Approve an amendment to effect a reverse stock split at a ratio between 1-for-2 and 1-for-30, with the exact ratio set by the board.
Proposal 2: Approve adjournment of the meeting if more time is needed to solicit votes for Proposal 1.
Both proposals are considered routine, allowing brokers discretionary voting authority.
Board unanimously recommends voting FOR both proposals.
Board of directors and corporate governance
Board retains discretion to implement or abandon the reverse stock split even if approved by shareholders.
No directors or executive officers have substantial interests in the reverse stock split beyond their shareholdings.
Procedures for shareholder communications and director nominations for the 2026 Annual Meeting are outlined.
Latest events from GRI Bio
- Lead candidate improved lung function and fibrosis biomarkers in IPF, with strong safety data.GRI
Corporate presentation16 Mar 2026 - Positive phase 2A IPF results and IND plans for lupus program signal strong pipeline momentum.GRI
Corporate Connect Webinar Series11 Feb 2026 - Strong cash position and positive clinical data support continued pipeline advancement.GRI
Q4 20254 Feb 2026 - Biopharma seeks up to $250M for immune therapies, advancing IPF and lupus programs amid high risk.GRI
Registration Filing30 Jan 2026 - Reverse stock split and adjournment proposals approved; results to be filed on Form 8-K.GRI
EGM 202615 Jan 2026 - Stockholders to vote on a reverse stock split to support Nasdaq compliance at a virtual meeting.GRI
Proxy Filing19 Dec 2025 - Registering 1.58M shares for resale from warrants, with proceeds only if warrants are exercised.GRI
Registration Filing16 Dec 2025 - H.C. Wainwright & Co. is exclusive underwriter, earning 7% fees and warrants, with no future right of first refusal.GRI
Registration Filing10 Dec 2025 - Biopharma seeks $8.6M to advance IPF and autoimmune drug pipeline amid financial and Nasdaq risks.GRI
Registration Filing8 Dec 2025